KEI Comments Regarding NIH Exclusive License to Memorial Sloan Kettering Cancer Center

(Update: The NIH provided a response to our comments on April 15, 2021.) Knowledge Ecology International (KEI) submitted comments on April 14, 2021 to the Federal Register notice for the National Institutes of Health’s (NIH) “Prospective Grant of Exclusive Patent… Continue Reading

KEI Comments on NIH Exclusive License to Norwegian Firm Zelluna

(Update: The NIH provided a response to our comments on April 15, 2021.) On Wednesday April 14, 2021, Knowledge Ecology International (KEI) filed comments with the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License:… Continue Reading

KEI Comments on NIH Proposed Exclusive License to Iovance for Cancer Cell Therapy

On Friday March 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Engineered Tumor Infiltrating Lymphocytes for Cancer Therapy” (86 FR 11548). The technology is… Continue Reading

KEI Comments on NIH Exclusive Licenses to Kyverna on CAR T therapy

(Update: The NIH provided responses to our comments on April 5, 2021 – 86 FR 10092 Response and 86 FR 10081 Response) On Friday March 5, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institute of Health (NIH)… Continue Reading

KEI Comments to NIH Proposed Exclusive License to Ziopharm for Cell Therapy Cancer Treatment

On February 9, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer” to Ziopharm Oncology, Inc. (Ziopharm). The… Continue Reading

KEI Comments on NIH Exclusive License to Canadian Firm EpifiZa

On Tuesday February 9, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Certain Fusion Proteins and Their Use for the Treatment… Continue Reading

KEI Comments to NIH on Exclusive and Co-Exclusive Licenses to Senti Bio

Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) on January 12, 2021 regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like… Continue Reading

KEI Comments on NIH Exclusive License to Morphiex for Cancer Treatment

(Update: The NIH provided a response to our comments on January 19, 2021) On January 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Use… Continue Reading

KEI Comments on Proposed Exclusive License to Connectyx for Degenerative Retinal Disease Treatment

On November 6, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the, “Prospective Grant of an Exclusive Patent License: Development of a Direct Ocular Administered Formulation of Metformin for Use in Therapeutic Treatment… Continue Reading

KEI Sues NIH over Improper Withholding of Three FOIA Requests

On September 29, 2020, Knowledge Ecology International (KEI) filed a lawsuit against the National Institutes of Health (NIH) regarding three Freedom of Information Act (FOIA) requests filed by KEI. The complaint filed by KEI requests injunctive, declaratory, and other appropriate… Continue Reading